

ABSTRACT OF THE DISCLOSURE

The present invention is directed to the use of antibodies or binding portions thereof or probes which
5 recognize an antigen of normal, benign, hyperplastic, and
cancerous prostate epithelial cells or portions thereof.
These antibodies or binding portions thereof or probes can
be labeled and used for detection of such cells. They also
can be used alone or bound to a substance effective to
10 ablate or kill such cells as a therapy for prostate cancer.
Also disclosed is a hybridoma cell line which produces a
monoclonal antibody recognizing antigens of normal, benign,
hyperplastic, and cancerous prostate epithelial cells or
portions thereof.